» Articles » PMID: 28130045

Hematopoietic Processes in Eosinophilic Asthma

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2017 Jan 29
PMID 28130045
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Airway eosinophilia is a hallmark of allergic asthma, and understanding mechanisms that promote increases in lung eosinophil numbers is important for effective pharmacotherapeutic development. It has become evident that expansion of hematopoietic compartments in the bone marrow (BM) promotes differentiation and trafficking of mature eosinophils to the airways. Hematopoietic progenitor cells egress the BM and home to the lungs, where in situ differentiation within the tissue provides an ongoing source of proinflammatory cells. In addition, hematopoietic progenitor cells in the airways can respond to locally derived alarmins to produce a panoply of cytokines, thereby themselves acting as effector proinflammatory cells that potentiate type 2 responses in eosinophilic asthma. In this review, we provide evidence for these findings and discuss novel targets for modulating eosinophilopoietic processes, migration, and effector function of precursor cells.

Citing Articles

CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.

Mohammad Taheri M, Javan F, Poudineh M, Athari S Clin Rev Allergy Immunol. 2024; 66(3):328-362.

PMID: 38995478 DOI: 10.1007/s12016-024-08998-0.


Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review.

Munari S, Ciotti G, Cestaro W, Corsi L, Tonin S, Ballarin A Drugs Context. 2024; 13.

PMID: 38817801 PMC: 11139165. DOI: 10.7573/dic.2024-3-5.


Different Transcriptome Features of Peripheral Blood Mononuclear Cells in Non-Emphysematous Chronic Obstructive Pulmonary Disease.

Imamoto T, Kawasaki T, Sato H, Tatsumi K, Ishii D, Yoshioka K Int J Mol Sci. 2024; 25(1).

PMID: 38203236 PMC: 10779039. DOI: 10.3390/ijms25010066.


Trained immunity in type 2 immune responses.

Hartung F, Esser-von Bieren J Mucosal Immunol. 2022; 15(6):1158-1169.

PMID: 36065058 PMC: 9705254. DOI: 10.1038/s41385-022-00557-0.


Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells.

Chen S, Chen G, Xu F, Sun B, Chen X, Hu W Cell Discov. 2022; 8(1):80.

PMID: 35973984 PMC: 9381771. DOI: 10.1038/s41421-022-00433-y.